Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
Rhea-AI Summary
Monte Rosa Therapeutics (Nasdaq: GLUE) will present updated interim results from the Phase 1/2 study of the GSPT1-directed molecular glue degrader MRT-2359 in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients.
The company will host a live conference call and webcast on December 16, 2025 at 8:00 a.m. ET. The presentation will be available via Monte Rosa’s investor site under “Events & Presentations,” and an archived webcast will be accessible for 30 days after the event.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
GLUE was down 1.51% pre-announcement while key biotech peers were mixed: ENGN -5.05%, CTNM -5.68%, FDMT -0.91%, with DRTS +1.2% and DSGN +1.4%. Moves do not indicate a unified sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Earnings & updates | Positive | +5.7% | Q3 2025 results plus Novartis collaboration and clinical pipeline progress. |
| Nov 03 | Investor conferences | Neutral | -6.1% | Planned CEO participation in multiple healthcare investor conferences. |
| Oct 24 | Preclinical data | Positive | +7.3% | Preclinical MRT-6160 data showing broad immune activity and disease reduction. |
| Sep 15 | Strategic partnership | Positive | +44.1% | Major Novartis collaboration with large upfront and milestone potential. |
| Sep 02 | Investor conferences | Neutral | +2.5% | Announcements of attendance at Morgan Stanley and Stifel healthcare events. |
Recent news events have consistently coincided with positive or constructive price reactions, including clinical and partnership updates, suggesting the stock has historically responded favorably to pipeline and business development news.
Over the last six months, Monte Rosa reported multiple catalysts. A Sept 15, 2025 Novartis collaboration with a $120M upfront and up to $5.7B potential value drove a 44.07% move. Preclinical MRT-6160 data on Oct 24, 2025 saw a 7.32% gain. Q3 2025 results and business updates on Nov 6, 2025 coincided with a 5.69% rise. Conference participation headlines showed more muted, mixed moves. Today’s MRT-2359 interim update fits the pattern of frequent R&D news flow building on this pipeline narrative.
Market Pulse Summary
This announcement schedules an interim update from the ongoing Phase 1/2 study of MRT-2359 in heavily pretreated mCRPC patients, with details to be discussed on December 16, 2025. It fits a pattern of frequent R&D communication, including prior preclinical and early clinical milestones. Investors may focus on efficacy and safety signals relative to earlier degrader programs, the durability of responses in metastatic disease, and how these results position MRT-2359 within Monte Rosa’s broader oncology strategy.
Key Terms
metastatic castration-resistant prostate cancer medical
AI-generated analysis. Not financial advice.
Conference call and webcast to be held at 8 a.m. ET on December 16, 2025
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Tuesday, December 16, 2025, at 8:00 a.m. ET. The webcast presentation will highlight interim clinical results from the ongoing Phase 1/2 study of the GSPT1-directed MGD MRT-2359 in heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC) patients.
A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com. Registration for the conference call is available at the following link. An archived version of the webcast will be made available for 30 days following the presentation.
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology and neurology. For more information, visit www.monterosatx.com.
Investors
Andrew Funderburk
ir@monterosatx.com
Media
Cory Tromblee, Scient PR
media@monterosatx.com
FAQ
When will Monte Rosa Therapeutics (GLUE) present MRT-2359 Phase 1/2 interim results?
What patient population is included in the MRT-2359 Phase 1/2 update for GLUE?
How can investors watch the Monte Rosa (GLUE) MRT-2359 presentation?
Will the MRT-2359 webcast for GLUE be available after the live presentation?
What drug is being discussed in Monte Rosa’s (GLUE) December 16, 2025 presentation?
Is registration required to join Monte Rosa Therapeutics (GLUE) conference call for MRT-2359 results?
